Vivorte
Vivorté is dedicated to developing innovative bone grafting and regenerative technologies aimed at improving the standard of care for surgeons, hospitals, and patients. The company's mission is to identify, develop, and commercialize orthopedic devices that maintain or improve bone strength while expediting healing, providing high-quality, cost-effective solutions.
Industries
Nr. of Employees
small (1-50)
Patents
Products
Trabexus (bone void filler kit)
Sterile, single-use kit containing a self-setting, resorbable calcium phosphate matrix combined with engineered partially demineralized allograft particles designed for surgical filling of bony voids and defects.
Fortera (injectable biocement kit)
Sterile, single-use kit containing a fully synthetic, self-setting, resorbable calcium phosphate cement formulated for high compressive strength and injectable delivery through a 16-gauge cannula.
Fortera®
Fortera is a biocompatible, self-setting, gradually resorbable, calcium phosphate cement supplied in a sterile, single use kit that transforms into a paste capable of flowing through a 16 gauge cannula.
Trabexus
Trabexus is a proprietary, biocompatible, self-setting, gradually resorbable, calcium phosphate matrix enhanced with partially demineralized allograft particles for optimized compressive strength and resorptive characteristics.
Trabexus (bone void filler kit)
Sterile, single-use kit containing a self-setting, resorbable calcium phosphate matrix combined with engineered partially demineralized allograft particles designed for surgical filling of bony voids and defects.
Fortera (injectable biocement kit)
Sterile, single-use kit containing a fully synthetic, self-setting, resorbable calcium phosphate cement formulated for high compressive strength and injectable delivery through a 16-gauge cannula.
Fortera®
Fortera is a biocompatible, self-setting, gradually resorbable, calcium phosphate cement supplied in a sterile, single use kit that transforms into a paste capable of flowing through a 16 gauge cannula.
Trabexus
Trabexus is a proprietary, biocompatible, self-setting, gradually resorbable, calcium phosphate matrix enhanced with partially demineralized allograft particles for optimized compressive strength and resorptive characteristics.
Services
Remote educational video material demonstrating product features and implantation technique for authorized users.
Partnerships and distribution agreements to commercialize orthobiologic product lines through established distributor networks.
Remote educational video material demonstrating product features and implantation technique for authorized users.
Partnerships and distribution agreements to commercialize orthobiologic product lines through established distributor networks.
Expertise Areas
- Orthobiologic materials for bone void filling
- Biocompatible calcium phosphate cement formulation
- Engineered allograft particle integration
- Preclinical testing and histology
Key Technologies
- Calcium phosphate cement chemistry
- Hydroxyapatite conversion
- Partially demineralized allograft particles
- Injectable paste and cannula delivery systems
News & Updates
March 13, 2020: Vivorté announced a distribution agreement with Acumed.
March 4, 2018: Mark Wagner was announced as the new CEO.
October 3, 2017: Launch of new bone grafting solutions.
January 7, 2017: Article highlighting the company's focus on bone healing.
January 3, 2017: Coverage of the company's efforts in bone repair.
July 21, 2016: Article on the company's research initiatives.
March 13, 2020: Vivorté announced a distribution agreement with Acumed.
March 4, 2018: Mark Wagner was announced as the new CEO.
October 3, 2017: Launch of new bone grafting solutions.
January 7, 2017: Article highlighting the company's focus on bone healing.
January 3, 2017: Coverage of the company's efforts in bone repair.
July 21, 2016: Article on the company's research initiatives.